Evidence map›Paper›PMID 37614366›Full record

ArticleMolecular and clinical oncology2023

Prognostic factors in renal cell carcinoma: A single‑center study.

Rawa M Ali, Dana N Muhealdeen, Saman S Fakhralddin, Rawa Bapir, Soran H Tahir, Rezheen J Rashid, Choman Sabah Omer, Hiwa O Abdullah, Berun A Abdalla, Shvan H Mohammed and 4 more

Open access · diamondAbstract read
In one paragraph

Article in Molecular and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 3 countries.

Rawa M AliScientific Affairs Department, Smart Health Tower, Sulaymaniyah, Kurdistan 46001, Iraq.
Dana N MuhealdeenDepartment of Oncology, Hiwa Hospital, Sulaymaniyah, Kurdistan 46001, Iraq.
Saman S FakhralddinScientific Affairs Department, Smart Health Tower, Sulaymaniyah, Kurdistan 46001, Iraq.
Rawa BapirScientific Affairs Department, Smart Health Tower, Sulaymaniyah, Kurdistan 46001, Iraq.
Soran H TahirScientific Affairs Department, Smart Health Tower, Sulaymaniyah, Kurdistan 46001, Iraq.
Rezheen J RashidScientific Affairs Department, Smart Health Tower, Sulaymaniyah, Kurdistan 46001, Iraq.
Choman Sabah OmerScientific Affairs Department, Smart Health Tower, Sulaymaniyah, Kurdistan 46001, Iraq.
Hiwa O AbdullahScientific Affairs Department, Smart Health Tower, Sulaymaniyah, Kurdistan 46001, Iraq.
Berun A AbdallaScientific Affairs Department, Smart Health Tower, Sulaymaniyah, Kurdistan 46001, Iraq.
Shvan H MohammedKscien Organization for Scientific Research, Sulaymaniyah, Kurdistan 46001, Iraq.
Fahmi H KakamadScientific Affairs Department, Smart Health Tower, Sulaymaniyah, Kurdistan 46001, Iraq.
Fakher AbdullahKscien Organization for Scientific Research, 3082 JJ Rotterdam, The Netherlands.
Muhammad KarimKscien Organization for Scientific Research, Tampa, FL 33637, USA.
Hawbash M RahimScientific Affairs Department, Smart Health Tower, Sulaymaniyah, Kurdistan 46001, Iraq.
Health Forecasting · USKurdistan Regional Government · IQNetherlands Organisation for Applied Scientific Research · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal cell carcinoma (RCC) is a heterogeneous and complex disease with numerous pathophysiologic variants. ~40% of patients succumb due to the progression of the disease, making RCC the most fatal of the common urologic malignancies. Prognostic factors are indicators of the progression of the disease, and the precise determination of these factors is important for evaluating and managing RCC. In the present study, it was aimed to determine and find associations among the histopathological features of RCCs and their impact on survival and metastasis. This is a cross-sectional study of RCC cases who have undergone partial or radical nephrectomy from March 2008 to October 2021 and have been pathologically reviewed at Shorsh General Teaching Hospital in Sulaimani, Iraq. The data in the pathology studies were supplemented by follow-up of the patients to obtain information about survival, recurrence and metastasis. In total, 228 cases of RCC were identified, among whom 60.5% were men and 39.5% were women, with a median age of 51 years. The main tumor types were clear cell RCC (71.1%), papillary RCC (13.6%), and chromophobe RCC (11%). Various measures of aggressiveness, including tumor necrosis, sarcomatoid change, microvascular invasion, and parameters of invasiveness (invasion of the renal sinus and other structures), were significantly correlated with each other, and they were also associated with reduced overall survival and an increased risk of metastasis on univariate analysis. However, on multivariate analysis, only tumor size and grade, and microvascular invasion retained statistical significance and were associated with a lower survival rate. In conclusion, pathological parameters have an impact on prognosis in RCC. The most consistent prognostic factors can be tumor size and grade, and microvascular invasion.

Indexed as

kidney cancermetastasisprognosisprognostic factorsrenal cell carcinoma

Identifiers

PMID37614366
PMCPMC10442722
OpenAlexW4384340055

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.